• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    11/23/23 8:05:48 AM ET
    $ATHE
    $AVGR
    $BWV
    $CYTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ATHE alert in real time by email

    Gainers

    • Heart Test Laboratories (NASDAQ:HSCS) stock rose 22.4% to $0.24 during Thursday's pre-market session. The company's market cap stands at $5.3 million.
    • NeuroOne Medical Tech (NASDAQ:NMTC) stock moved upwards by 14.68% to $1.46. The market value of their outstanding shares is at $34.8 million.
    • PaxMedica (NASDAQ:PXMD) stock increased by 13.48% to $0.91.
    • Blue Water Biotech (NASDAQ:BWV) shares increased by 12.11% to $0.36. The company's market cap stands at $6.4 million. The company's, Q3 earnings came out 4 days ago.
    • OpGen (NASDAQ:OPGN) stock rose 11.7% to $0.46. The company's market cap stands at $4.9 million.
    • Avinger (NASDAQ:AVGR) stock increased by 10.63% to $3.33. The company's market cap stands at $4.5 million.

    Losers

    • Alterity Therapeutics (NASDAQ:ATHE) stock declined by 19.8% to $1.91 during Thursday's pre-market session. The market value of their outstanding shares is at $7.7 million.
    • UpHealth (NYSE:UPH) stock decreased by 17.79% to $0.65. The company's market cap stands at $11.1 million.
    • First Wave BioPharma (NASDAQ:FWBI) stock fell 17.61% to $0.22. The market value of their outstanding shares is at $2.9 million.
    • SILO Pharma (NASDAQ:SILO) shares decreased by 13.59% to $1.59. The market value of their outstanding shares is at $4.9 million.
    • TRACON Pharma (NASDAQ:TCON) stock decreased by 11.2% to $0.19. The market value of their outstanding shares is at $6.0 million.
    • Altamira Therapeutics (NASDAQ:CYTO) stock fell 10.3% to $0.33. The company's market cap stands at $2.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATHE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHE
    $AVGR
    $BWV
    $CYTO

    CompanyDatePrice TargetRatingAnalyst
    NeuroOne Medical Technologies Corporation
    $NMTC
    5/5/2025$1.45Buy
    Ladenburg Thalmann
    Alterity Therapeutics Limited
    $ATHE
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    Alterity Therapeutics Limited
    $ATHE
    12/12/2024$8.00Buy
    Maxim Group
    UpHealth Inc.
    $UPH
    3/31/2022$6.00 → $1.00Buy → Hold
    Lake Street
    NeuroOne Medical Technologies Corporation
    $NMTC
    3/29/2022$6.00 → $2.00Buy → Hold
    Craig Hallum
    TRACON Pharmaceuticals Inc.
    $TCON
    2/23/2022$10.00Outperform
    Baird
    First Wave BioPharma Inc.
    $FWBI
    12/7/2021Buy → Hold
    Maxim Group
    NeuroOne Medical Technologies Corporation
    $NMTC
    12/3/2021$5.75Buy
    Alliance Global Partners
    More analyst ratings

    $ATHE
    $AVGR
    $BWV
    $CYTO
    SEC Filings

    View All

    Silo Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Silo Pharma, Inc. (0001514183) (Filer)

    2/23/26 5:00:43 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Silo Pharma Inc.

    SCHEDULE 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

    2/17/26 10:24:44 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

    2/17/26 8:00:51 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $ATHE
    $AVGR
    $BWV
    $CYTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $ATHE
    $AVGR
    $BWV
    $CYTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Silo Pharma Announces Share Buyback Program

    Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements.   The Company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as repo

    2/23/26 4:15:00 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

    SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder (PTSD). The allowed application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," strengthens Silo's growing intellectual-proper

    2/18/26 8:28:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    University of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center

    Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (NASDAQ:HSCS; HSCSW), HSCSW) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that the University of the West of England ("UWE") has adopted the Company's MyoVista Insights™ platform and MyoVista® wavECG™ device as its exclusive ECG technologies to establish a Reference Center for ECG Education and Technology. Under the agreement, MyoVista Insights and the MyoVista wavECG device will be used exclusively across UWE's cardiac and physiological science teaching pro

    2/5/26 8:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    $ATHE
    $AVGR
    $BWV
    $CYTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Mertens Steve covered exercise/tax liability with 7,376 shares, decreasing direct ownership by 5% to 153,047 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:27:42 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Business Development Director Christianson Mark covered exercise/tax liability with 1,812 shares, decreasing direct ownership by 0.79% to 228,920 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:20:36 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    CEO and President Rosa David A covered exercise/tax liability with 71,325 shares, decreasing direct ownership by 6% to 1,082,590 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:15:19 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $ATHE
    $AVGR
    $BWV
    $CYTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Numerical Tech with a new price target

    Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45

    5/5/25 8:32:14 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Alterity Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

    2/3/25 7:02:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Alterity Therapeutics with a new price target

    Maxim Group initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $8.00

    12/12/24 8:39:51 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $AVGR
    $BWV
    $CYTO
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advance into Phase 3. We accomplished this mission and then some. Results from the Phase 2 trials were resoundingly favourable with data demonstrating the drug to be safe and well-tolerated

    1/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

    Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

    8/5/25 8:32:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $ATHE
    $AVGR
    $BWV
    $CYTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $ATHE
    $AVGR
    $BWV
    $CYTO
    Financials

    Live finance-specific insights

    View All

    Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

    Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

    10/6/25 8:10:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

    Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 ("FQ1 2026") and provided a business update highlighting continued progress. First Quarter and Recent Highlights HeartSciences has made substantial progress during FQ1 2026 which saw the Company achieve an FDA Breakthrough Device Designation and successfully launched MyoVista Insights. MyoVista Insights™ Software Platform HeartScie

    9/11/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%

    Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the third quarter of fiscal year 2025 ended June 30, 2025. Recent Company Highlights Product revenue increased 105% to $1.7 million in the third quarter of fiscal year 2025, compared to $0.8 million in the third quarter of fiscal year 2024.Product gross margin expanded significantly to 53.9% in the third

    8/14/25 7:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care